Model Medicines utilizes artificial intelligence and data science to accelerate the discovery and development of novel therapeutics across virology and oncology. The company focuses on generating drug candidates with best-in-class potential, evidenced by 192 compounds discovered and 67 assets advanced in cellular disease models. Their platform, GALILEO™, integrates biology and data science to efficiently move validated assets toward clinical relevance.
Funding
$15.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods are slow, expensive, and often fail to produce effective therapeutics for diseases with high unmet medical needs. Identifying promising drug candidates from vast chemical spaces and validating their efficacy across multiple disease models remains a significant challenge.
Solution
Model Medicines leverages an AI-driven drug discovery platform, GALILEO™, to accelerate the identification and development of novel therapeutics. By integrating data science, machine learning, medicinal chemistry, and biology, the platform identifies relevant data from primary literature and employs advanced pharmacophore modeling to create "Built-for-Purpose" datasets. This approach enables the exploration of extensive chemical landscapes, accurate prediction of promising compounds, and the creation of best-in-class therapeutics for oncology, infectious diseases, and other areas of unmet medical need. The company focuses on discovering drugs with best-in-class potential against rigorous target product profiles, rather than generating numerous hits that may not reach clinical trials.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and healthcare providers seeking to accelerate drug discovery and develop novel therapeutics for diseases with high unmet medical needs.
Features
- GALILEO™ AI platform for identifying and extracting relevant data from primary literature sources
- Advanced pharmacophore modeling and hypothesis-driven data mining techniques
- Discovery of novel chemical entities (NCEs) with pan-antiviral activity
- Preclinical candidate MDL-4101, a novel-acting small molecule inhibitor of BRD4 for oncology
- Validated drug candidates across oncology, infectious diseases, GI, and neurology
- In silico program for autoimmune and rare diseases